Embecta (NASDAQ:EMBC) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Embecta (NASDAQ:EMBC) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Several other brokerages have also commented on EMBC. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. BTIG Research reaffirmed a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. Finally, Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $18.50.

Embecta Stock Performance

Embecta stock opened at $12.01 on Friday. The stock has a market cap of $711.11 million, a P/E ratio of 7.37 and a beta of 1.10. Embecta has a fifty-two week low of $9.20 and a fifty-two week high of $21.23. The firm’s fifty day moving average price is $13.06 and its 200-day moving average price is $12.62.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.04. The firm had revenue of $263.30 million during the quarter, compared to analyst estimates of $265.66 million. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The company’s revenue was down 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Embecta will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Friday, December 5th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 5.0%. The ex-dividend date of this dividend was Friday, December 5th. Embecta’s dividend payout ratio is currently 36.81%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Laurel Wealth Advisors LLC lifted its stake in shares of Embecta by 754.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,871 shares of the company’s stock valued at $193,000 after purchasing an additional 1,652 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the period. Banque Transatlantique SA grew its holdings in Embecta by 879.1% during the 1st quarter. Banque Transatlantique SA now owns 3,701 shares of the company’s stock valued at $44,000 after purchasing an additional 3,323 shares during the last quarter. Wexford Capital LP purchased a new stake in Embecta in the 3rd quarter worth about $94,000. Finally, Tower Research Capital LLC TRC lifted its stake in Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares during the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.